| Citation: |
LI Haoran, WANG Yali, LI Hongjuan, XIANG Yuancui, LIU Huimin. Effect of lncRNA FAL1 on Chemotherapy Resistance of Ovarian Cancer Cells by Regulating MAPK Pathway and Related Mechanism[J]. Cancer Research on Prevention and Treatment, 2021, 48(4): 333-340. DOI: 10.3971/j.issn.1000-8578.2021.20.0752
|
To observe the expression difference of lncRNA FAL1 in ovarian cancer cells and their drug-resistant cell lines, and to explore the effect and mechanism of lncRNA FAL1 down-regulation on cell chemotherapy resistance.
The expression levels of fal1 gene in SKOV3 and COC1 cells and their drug-resistant cell lines were detected by qRT-PCR. fal1 siRNA was transfected to downregulate fal1 gene expression. MTT was used to detect cell proliferation. Transwell method was used to detect cell invasion ability. Plate clone formation test was used to detect cell clone ability, and Western blot was used to detect MDR-1, mpr-1, ABCG2 and phosphorylation levels of p38 MAPK, ERK1/2 and JNK. SKOV3/DDP and COC1/DDP cells transfected with FAL1-siRNA were injected subcutaneously into BALB/c nude mice. The volume and mass of subcutaneous transplanted tumors were measured.
Compared with SKOV3 and COC1 cells, SKOV3/DDP and COC1/DDP cells were less sensitive to DDP, and the expression levels of FAL1 gene increased (P < 0.01). After transfection with FAL1-siRNA, the sensitivity of SKOV3/DDP and COC1/DDP cells to DDP increased (P < 0.01), and the invasion (P < 0.05) and cloning ability (P < 0.01) decreased. The expression levels of MDR-1, MPR-1, ABCG2 (P < 0.01) and the phosphorylation levels of p38 MAPK, ERK1/2 and JNK (P < 0.05) decreased. The volume and mass of subcutaneous transplanted tumors were significantly reduced (P < 0.01).
Down-regulation of lncRNA FAL1 could significantly reduce the chemotherapy resistance of cisplatin-resistant ovarian cancer cell lines and inhibit the proliferation of drug-resistant cells in vivo. Its mechanism is related to inhibiting the activation of MAPK signaling pathway.
| [1] |
Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018[J]. CA Cancer J Clin, 2018, 68(4): 284-296. doi: 10.3322/caac.21456
|
| [2] |
Odunsi K. Immunotherapy in ovarian cancer[J]. Ann Oncol, 2017, 28(suppl_8): viii1-viii7.
|
| [3] |
Wilusz JE. Long noncoding RNAs: Re-writing dogmas of RNA processing and stability[J]. Biochim Biophys Acta, 2016, 1859(1): 128-138. doi: 10.1016/j.bbagrm.2015.06.003
|
| [4] |
Peng WX, Koirala P, Mo YY. LncRNA-mediated regulation of cell signaling in cancer[J]. Oncogene, 2017, 36(41): 5661-5667. doi: 10.1038/onc.2017.184
|
| [5] |
Zhu CH, Xiao DH, Dai LG, et al. Highly expressed lncRNA FAL1 promotes the progression of gastric cancer by inhibiting PTEN[J]. Eur Rev Med Pharmacol Sci, 2018, 22(23): 8257-8264. http://www.ncbi.nlm.nih.gov/pubmed/?term=Highly%20expressed%20lncRNA%20FAL1%20promotes%20the%20progression%20of%20gastric%20cancer%20by%20inhibiting%20PTEN.
|
| [6] |
Wu K, Zhang N, Ma J, et al. Long noncoding RNA FAL1 promotes proliferation and inhibits apoptosis of human colon cancer cells[J]. IUBMB Life, 2018, 70(11): 1093-1100. doi: 10.1002/iub.1880
|
| [7] |
Jeong S, Lee J, Kim D, et al. Relationship of focally amplified long noncoding on chromosome 1 (FAL1) lncRNA with E2F transcription factors in thyroid cancer[J]. Medicine (Baltimore), 2016, 95(4): e2592. doi: 10.1097/MD.0000000000002592
|
| [8] |
柴冬亚, 袁佳琪, 周轶平. MAPK信号通路影响肿瘤多药耐药的研究进展[J]. 中国新药杂志, 2019, 28(8): 948-953. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201908010.htm
Chai DY, Yuan JQ, Zhou YP. Research progress of MAPK signaling pathway for multidrug resistance in tumors[J]. Zhongguo Xin Yao Za Zhi, 2019, 28(8): 948-953. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXYZ201908010.htm
|
| [9] |
Li J, Li Z, Zheng W, et al. LncRNA-ATB: An indispensable cancer-related long noncoding RNA[J]. Cell Prolif, 2017, 50(6): e12381. doi: 10.1111/cpr.12381
|
| [10] |
Huang Y. The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases[J]. J Cell Mol Med, 2018, 22(12): 5768-5775. doi: 10.1111/jcmm.13866
|
| [11] |
Zhang Z, Qian W, Wang S, et al. Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma[J]. Cell Physiol Biochem, 2018, 49(5): 1778-1791. doi: 10.1159/000493623
|
| [12] |
Wang L, Cho KB, Li Y, et al. Long noncoding RNA (lncRNA)-mediated competing endogenous RNA networks provide novel potential biomarkers and therapeutic targets for colorectal cancer[J]. Int J Mol Sci, 2019, 20(22): 5758. doi: 10.3390/ijms20225758
|
| [13] |
Li J, Yang C, Li Y, et al. LncRNA GAS5 suppresses ovarian cancer by inducing inflammasome formation[J]. Biosci Rep, 2018, 38(2): BSR20171150. doi: 10.1042/BSR20171150
|
| [14] |
Liang H, Yu T, Han Y, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression[J]. Mol Cancer, 2018, 17(1): 119. doi: 10.1186/s12943-018-0870-5
|
| [15] |
Lv X, Li Y, Li Y, et al. FAL1: A critical oncogenic long non-coding RNA in human cancers[J]. Life Sci, 2019, 236: 116918. doi: 10.1016/j.lfs.2019.116918
|
| [16] |
Zhang Q, Len TY, Zhang SX, et al. Exosomes transferring long non-coding RNA FAL1 to regulate ovarian cancer metastasis through the PTEN/AKT signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2020, 24(1): 43-54. http://www.researchgate.net/publication/338738212_Exosomes_transferring_long_non-coding_RNA_FAL1_to_regulate_ovarian_cancer_metastasis_through_the_PTENAKT_signaling_pathway
|
| [17] |
Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer[J]. Nat Rev Cancer, 2018, 18(7): 452-464. doi: 10.1038/s41568-018-0005-8
|
| [18] |
Eid SY, Althubiti MA, Abdallah ME, et al. The carotenoid fucoxanthin can sensitize multidrug resistant cancer cells to doxorubicin via induction of apoptosis, inhibition of multidrug resistance proteins and metabolic enzymes[J]. Phytomedicine, 2020, 77: 153280. doi: 10.1016/j.phymed.2020.153280
|
| [19] |
Liu F, Yang X, Geng M, et al. Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy[J]. Acta Pharm Sin B, 2018, 8(4): 552-562. doi: 10.1016/j.apsb.2018.01.008
|
| [20] |
Sullivan RJ, Infante JR, Janku F, et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase Ⅰ Dose-Escalation and Expansion Study[J]. Cancer Discov, 2018, 8(2): 184-195. doi: 10.1158/2159-8290.CD-17-1119
|
| [21] |
Tang G, Zeng Z, Sun W, et al. Small Nucleolar RNA 71A Promotes Lung Cancer Cell Proliferation, Migration and Invasion via MAPK/ERK Pathway[J]. J Cancer, 2019, 10(10): 2261-2275. doi: 10.7150/jca.31077
|
| [1] | ZHENG Yu, PAN Hongming. Progress of Targeted Therapy and Immunotherapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2024, 51(4): 234-239. DOI: 10.3971/j.issn.1000-8578.2024.23.1257 |
| [2] | SHI Chao, ZHANG Xiangmei, LIU Yunjiang. Research Progress on Immunization and Targeted Therapy for Triple-negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(7): 710-716. DOI: 10.3971/j.issn.1000-8578.2023.22.1426 |
| [3] | JI Xiaojun, ZHAO Tingli, MIAO Lei, SI Yaxuan, WU Jian, XU Dan. Progress in Development of Targeted Therapeutic Drugs for Acute Myeloid Leukemia[J]. Cancer Research on Prevention and Treatment, 2023, 50(4): 413-421. DOI: 10.3971/j.issn.1000-8578.2023.22.1056 |
| [4] | LIU Shanting, QIN Jiali, FAN Jie. Dawn of Advanced Thyroid Cancer Therapy: Targeted Therapy and Immunotherapy[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 6-11. DOI: 10.3971/j.issn.1000-8578.2023.22.0869 |
| [5] | CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 727-732. DOI: 10.3971/j.issn.1000-8578.2022.21.1241 |
| [6] | CHEN Weichang, SHI Tongguo, ZHU Jinghan, SUN Linqing, LI Juntao. Progress on Immunotherapy of Gastrointestinal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 639-643. DOI: 10.3971/j.issn.1000-8578.2022.21.1527 |
| [7] | SUN Lu, SHI Hongwei, PI Guoliang. Advances in Molecular Targeting and Immunotherapy on Angiosarcomas[J]. Cancer Research on Prevention and Treatment, 2022, 49(1): 62-66. DOI: 10.3971/j.issn.1000-8578.2022.21.1045 |
| [8] | ZHANG Qiang, WU Shaoya, ZHANG Jing. New Insight on Tumor Microenvironment Remodelling and Augmented Therapeutic Efficacy of Immunotherapy by Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2021, 48(1): 1-6. DOI: 10.3971/j.issn.1000-8578.2021.20.0836 |
| [9] | WANG Xin, XU Huimian. Advances of Targeted Therapy and Immune Checkpoint Therapy on Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2020, 47(12): 905-908. DOI: 10.3971/j.issn.1000-8578.2020.20.0252 |
| [10] | ZHANG Yanli, ZHU Shunqin, LIU Yaling, CUI Hongjuan. 恶性黑色素瘤内科治疗研究进展[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 74-78. DOI: 10.3971/j.issn.1000-8578.2014.01.017 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: